Plant molecular farming application: Transgenic plants engineered to carry genes encoding cytokines and blood-clotting factors are primarily used for which purpose?

Introduction / Context:
Plants can be engineered to produce valuable therapeutic proteins. When genes for cytokines, clotting factors, or other human biologics are inserted into plant genomes, the resulting transgenic plants act as low-cost, scalable bioreactors. This strategy is commonly called molecular farming or biopharming.

Given Data / Assumptions:

• The inserted genes encode medical proteins such as cytokines and blood-clotting factors.
• Plants can synthesize, fold, and accumulate these proteins in leaves, seeds, or specialized compartments.
• The question asks for the primary intended use.

Concept / Approach:
The presence of therapeutic protein genes clearly points to pharmaceutical manufacture. While plants can also be engineered for nutrition, textiles, or fuels, cytokines and clotting factors are not nutrients, fibers, or fuels; they are biotherapeutics for treating disease.

Step-by-Step Solution:

Verification / Alternative check:
Case studies include plant-made clotting factor IX and cytokines produced in tobacco or cereal seeds for downstream purification, demonstrating feasibility and cost advantages.

Why Other Options Are Wrong:

Common Pitfalls:
Confusing vaccine-only applications with broader biopharmaceutical production; overlooking that the same platform can produce antibodies, enzymes, and hormones.

Final Answer:
Pharmaceutical production (biopharming/medical proteins).